MA-NETWITNESS
10.8.2022 20:02:09 CEST | Business Wire | Press release
NetWitness , a globally trusted provider of cybersecurity technologies and incident response, today announced the upcoming availability of NetWitness Platform XDR 12 later this month, the industry’s most comprehensive extended detection and response solution. NetWitness Platform XDR 12 is the first solution on the market to deliver on the promise of extended detection and response.
Developed in response to real-world customer needs, NetWitness Platform XDR 12 is focused on sophisticated detection, which is at the core of effective threat defense. The updated platform offers full visibility into all key data planes across an organization including network, logs, endpoint, and Internet of Things (IoT); full Security Orchestration, Automation, and Response (SOAR); a complete Threat Intelligence Platform (TIP); User and Entity Behavior Analytics (UEBA); and new asset analytics and prioritization, all easily viewed in a single interface and a unified data model.
“Effective security teams need tools that can bring insights together from multiple data sources and deliver comprehensive, actionable alerting,” said Kevin Bowers, Director, Product Management at NetWitness. “Embracing this principle, NetWitness built XDR functionality long before the phrase was popularized. This release delivers the promise of XDR: the ability for security teams to detect attacks across all an organization's information assets and infrastructure, and to stop them before they cause damage.”
The updated NetWitness Platform XDR solution features new and enhanced analytics capabilities that can find known and unknown threats even faster, to reduce dwell time and allow response and remediation before adversaries can successfully execute a harmful attack. NetWitness Platform XDR 12 also makes it easier for users to deploy and manage threat detection content bundles that target specific threat categories, vertical industries, and use cases, providing more effective threat coverage.
NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and to develop the tools to detect and respond to them. Since then, the technology has continuously evolved in real-world usage to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response. With its long history and global footprint, NetWitness Platform XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.
“XDR concepts aren’t new, but they’re incredibly important,” said Bill Hart, Senior Product Manager for NetWitness Platform XDR. “We long ago integrated the primary data planes – network, endpoint, log and IoT – into a unified data model allowing for advanced detection capabilities that are independent of the data source. Others that have recently adopted an XDR strategy still analyze different data types in silos and attempt to correlate at the alert level; this leaves visibility gaps. Sophisticated, multi-vector attack detection requires holistic, data level integration and analysis.”
To learn more about the new NetWitness Platform XDR 12, visit netwitness.com . Additionally, those attending the Black Hat Conference in Las Vegas on August 6-11 are encouraged to stop by the NetWitness booth (2941) for a NetWitness Platform XDR 12 product demo.
About NetWitness
NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com .
©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220810005133/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom